AstraZeneca's Qternmet XR, a combination therapy that contains dapagliflozin, metformin and saxagliptin, has been approved by the FDA as an adjunct to diet and exercise for patients with type 2 diabetes. The approval was based on the results of two Phase III trials, both of which showed significant HbA1C reductions among those given the drug.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.